Browse by Medical Category
Accepting New Patients
Go To Programs
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
View my most recent publications at PubMed
A new targeted therapy drug against EGFR-mutation driven lung tumors that have become resistant to current therapies shows activity against the most common resistance mutation, significantly improving outcomes for patients.
The Henri and Belinda Termeer Center for Targeted Therapies in the MGH Cancer Center has three new endowed leadership positions.
A detailed analysis of lung tumors that became resistant to targeted therapy drugs has revealed two previously unreported resistance mechanisms. The report also describes how the cellular nature of some tumors can change in response to treatment and finds how resistance-conferring mutations can disappear after treatment is discontinued.
coverage of study led by MGH investigator Lecia Sequist
quotes MGH physician Lecia Sequist
Back to Top